<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>It was postulated that <z:chebi fb="1" ids="3098">bile acids</z:chebi> can interact with esophageal epithelia of rats, either by the gastro-duodeno-esophageal anastomosis operation, or by adding bile concentrate to the diet </plain></SENT>
<SENT sid="1" pm="."><plain>These interactions would cause reflux diseases and eventually <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Rats gastrectomized and jejunostomized to allow <z:chebi fb="1" ids="3098">bile acids</z:chebi> to reflux into the esophagus developed many <z:mp ids='MP_0002038'>carcinomas</z:mp> in 50 weeks, while other modifications that kept bile out of the esophagus did not produce any <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e>, thus supporting the hypothesis </plain></SENT>
<SENT sid="3" pm="."><plain>Therefore, we conclude that <z:chebi fb="1" ids="3098">bile acids</z:chebi> refluxing into the esophagus of humans should also cause <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>, especially in Westernized societies with their high fat diets, which provide an abundant supply of bile </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="1" ids="3098">Bile acids</z:chebi> can enter the model OE33 cells and activate the oncogene c-myc at pH 4, the gene complex NF-kappaB at pH 6.5, and start proliferation at neutral pH </plain></SENT>
<SENT sid="5" pm="."><plain>50% of Barrett's <z:mpath ids='MPATH_160'>metaplasia</z:mpath> contained activated c-myc, and 40% of <z:hpo ids='HP_0100580'>Barrett's Esophagus</z:hpo> patients contain activated NF-kappaB </plain></SENT>
<SENT sid="6" pm="."><plain>Since <z:mpath ids='MPATH_458'>normal</z:mpath> human esophageal epithelia contained neither activated c-myc nor NF-kappaB, these activations must also occur in Barrett's patients </plain></SENT>
<SENT sid="7" pm="."><plain>Acid suppression therapy is used to treat these patients, and will solubilize free <z:chebi fb="1" ids="3098">bile acids</z:chebi> and some of the glycine conjugates, allowing them to enter the epithelia </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="5" ids="15891">Taurine</z:chebi> conjugates (20% of bile) will also enter the epithelia unaffected by acid suppression therapy </plain></SENT>
<SENT sid="9" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> these internalized <z:chebi fb="1" ids="3098">bile acids</z:chebi> will start <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>Therefore, techniques to keep <z:chebi fb="1" ids="3098">bile acids</z:chebi> out of the stomach, or prevent them from reacting, must be developed, but until then, acid suppression therapy should be restricted, not promoted </plain></SENT>
</text></document>